Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Foghorn Therapeutics to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, risk, analyst recommendations and profitability.
Volatility and Risk
Foghorn Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics’ peers have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Foghorn Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Foghorn Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
| Foghorn Therapeutics Competitors | 9789 | 15070 | 45344 | 1572 | 2.54 |
Foghorn Therapeutics presently has a consensus target price of $6.14, suggesting a potential upside of 192.52%. As a group, “Biotechnology” companies have a potential upside of 93.66%. Given Foghorn Therapeutics’ higher probable upside, equities analysts clearly believe Foghorn Therapeutics is more favorable than its peers.
Profitability
This table compares Foghorn Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Foghorn Therapeutics | -175.78% | N/A | -31.17% |
| Foghorn Therapeutics Competitors | -9,051.23% | -201.20% | -30.64% |
Valuation & Earnings
This table compares Foghorn Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Foghorn Therapeutics | $30.91 million | -$74.28 million | -2.14 |
| Foghorn Therapeutics Competitors | $726.68 million | $12.25 million | -10.19 |
Foghorn Therapeutics’ peers have higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Foghorn Therapeutics peers beat Foghorn Therapeutics on 7 of the 13 factors compared.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
